Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study
Clinical trial NCT07075250 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07075250
- Sponsor
- Peking University People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2028-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.